Lung Cancer Clinical Trials
COCOON
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib
KontRASt-02
A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer’
CRB-701
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an
Antibody-drug Conjugate Targeting Nectin-4, in Patients with Advanced Solid Tumors
AB598
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants with Advanced Malignancies
GEN1042
A First-in-Human, Open-label, Dose-escalation Trial with Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects with Malignant Solid Tumors
AVANZAR_D926NC00001
A Phase 3 Randomized open label global study of Dato-DXd in combination with Durvalumab and Carboplatin Versus Pembrolizumab in combination with Platinum based Chemo for the first-in-line treatment of patients with locally advanced or metastatic NSCLC without actionable Genomic alterations - AVANZAR.
HLX10-020-SCLC302
A Randomized, Open label study of HLX10 Plus Chemo(Carboplatin-Etoposide) in comparison with Atezolizumab + Chemo in previously untreated US patients with extensive stage small cell lung cancer - ASTRIDE.
COPERNICUS
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in a combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab Combination with Platinum-Based Chemotherapy as Second-line Treatment, EGFR-Mutated Locally Advanced or Metastatic NSCLC.
TEMPUS GEMINI NSCLC STUDY
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC)